Clinical trials: Acute Circulatory Failure
Hypertension, Heart Failure
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)
The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) clevidipine as compared with standard of care IV antihypertensive agents for blood pressure (BP) lowering in patients with acute heart failure…
- Trial name
- PRONTO (NCT00803634)
- Testing
- Clevidipine, Standard of Care IV antihypertensive
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 117 people
- Sponsor
- The Medicines Company
Congestive Heart Failure
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
In congestive heart failure, cardiac output is low, blood pressure is high, and the body becomes congested with fluid. In normal people, when there is high blood pressure, the heart muscle cells secrete a hormone that excretes…
- Trial name
- PPG1 (NCT00387621)
- Testing
- Nesiritide, Saline
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Horng Chen
Heart Decompensation
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties…
- Trial name
- NCT00475852
- Testing
- Nesiritide
- Where
- 328 sites in United States, Argentina and 26 more
- Volunteers
- 7,141 people
- Sponsor
- Scios, Inc.
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Coronary Syndrome, Heart Failure
Pharmacist Intervention to Decrease Medication Errors in Heart Disease Patients (The PILL-CVD Study)
Many people who have recently left the hospital have difficulties managing their medications, and medication errors are common. Patients with low health literacy levels may have a particularly difficult time understanding…
- Trial name
- PILL-CVD (NCT00632021)
- Testing
- Pharmacist Intervention for Low-Literacy in Cardiovascular Disease
- Where
- 2 sites in United States
- Volunteers
- 862 people
- Sponsor
- Vanderbilt University Medical Center
Heart Failure; With Decompensation
Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
There will be two populations in this study: control group, and intervention group. These groups will undergo propensity matching to account for confounders and minimize selection bias.
- Trial name
- CATAS-HF (NCT04095416)
- Testing
- ACE compression wrap
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Henry Ford Health System
Heart Failure
Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart failure is a serious condition in which the heart's ability to pump blood through the body is impaired, often making a person feel weak or fatigued.
- Trial name
- CARRESS (NCT00608491)
- Testing
- Stepped pharmacologic care, Ultrafiltration
- Where
- 9 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- Duke University
Heart Failure
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid…
- Trial name
- NCT00577135
- Testing
- Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification
- Where
- 9 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- Duke University
Acute Kidney Injury, Acute Renal Failure
A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation
Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated.
- Conditions
- Acute Kidney Injury, Acute Renal Failure, Heart Failure
- Trial name
- NCT01318811
- Testing
- Dilute unfractionated heparin, Standard concentration unfractionated heparin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Myocardial Infarction, Coronary Revascularization
Transfusion Trigger After Operations in High Cardiac Risk Patients
The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is…
- Conditions
- Myocardial Infarction, Coronary Revascularization, Acute Renal Failure
- Trial name
- TOP (NCT03229941)
- Testing
- Blood Transfusion
- Where
- 16 sites in United States
- Volunteers
- 1,424 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Acute Myocardial Infarction, Pacing Therapy
Post-Myocardial Infarction Remodeling Prevention Therapy
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial…
- Conditions
- Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure
- Trial name
- PRomPT (NCT01213251)
- Testing
- Single Site Pacing, Dual Site Pacing
- Where
- 26 sites in United States, Denmark and 5 more
- Volunteers
- 129 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Heart Failure Acute
B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27% of patients are re-hospitalized or die.
- Conditions
- Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
- Trial name
- BLUSHED-AHF (NCT03136198)
- Testing
- LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic
- Where
- 6 sites in United States
- Volunteers
- 130 people
- Sponsor
- Indiana University
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003270
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor…
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission
- Trial name
- NCT03192397
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute